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intraoperative revision for malplaced screws during the index procedure. Results 
of 10 case series and a European registry show rates of pedicle screw placement 
accuracy (0 mm to ≤ 2 mm) between 95% and 100% with 3D O-arm surgical imag-
ing with navigation compared to 84% - 95% reported for various current practice 
options from multiple meta-analyses. In addition, accuracy rates of between 72% 
and 92% have been reported for 2D C-arm without navigation. Economic studies 
demonstrated 3D O-arm surgical imaging with navigation has the potential to 
reduce the cost of fusion procedures in Europe and the USA by negating the need 
for pre-operative and post-operative imaging associated with current standard-
of-care, reducing the need for reoperations for screw revision, shortening length 
of procedures and OR time. It has been estimated that it could reduce the cost 
of hospitalization for spinal surgery by at least 3.8%. ConClusions: Current 
evidence shows 3D O-arm surgical imaging with navigation substantially reduces 
the human and financial burden of patients during spinal stabilization surgery 
compared with standard practice.
PMS11
Evaluating thE Efficacy of BioSiMilar inflixiMaB with thE acr50 
rESPonSE in PatiEntS with rhEuMatoid arthritiS; a MEta-analySiS in 
BayESian fraMEwork
Brodszky V., Gulacsi L., Balogh O., V. Hevér N., Baji P., Péntek M.
Corvinus University of Budapest, Budapest, Hungary
objeCtives: To identify all relevant literature on clinical efficacy and safety evi-
dence for biosimilar infliximab (CT-P13) and comparator biological medications in 
rheumatoid arthritis and to conduct an up-to-date meta-analysis. Methods: The 
following comparators were considered for this analysis: abatacept, adalimumab, 
certolizumab, etanercept, golimumab, infliximab, rituximab and tocilizumab. A 
MEDLINE search was conducted until March 2013. The Cochrane Highly Sensitive 
Search Strategy was applied to identify randomized controlled publications and was 
combined with ‘arthritis, rheumatoid’ MeSH terms and drug names. Randomized, 
controlled, clinical trials with adults with moderate-to-severe RA and reporting end-
points for 6 months where the full paper can be obtained were included. Direct and 
indirect evidences were combined in a mixed treatment comparisons in a Bayesian 
framework. Efficacy measured by ACR50 endpoint and frequency of serious adverse 
events at 24-30 weeks were analysed. Results: Altogether 41 trials were included 
into current meta-analysis. The relative odds ratios (and 95% credible intervals) for 
ACR50 of biosimilar infliximab treatments compared to abatacept, adalimumab, cer-
tolizumab, etanercept, golimumab, rituximab, tocilizumab and infliximab were 1.0 
(0.3-3.8), 0.9 (0.2-3.4), 0.3 (0.1-1.4), 1.0 (0.2-4.2), 1.2 (0.3-5.1), 0.9 (0.2-3.6), 0.5 (0.1-2.2), 
1.0 (0.3-3.2), respectively. Similarly, relative odds ratios for serious adverse events 
were 1.9 (0.8-4.8), 2.0 (0.6-5.8), 0.7 (0.2-2.1), 2.0 (0.8-5.7), 1.5 (0.5-4.2), 1.1 (0.7-2.0), 1.3 
(0.8-2.2), 1.3 (0.8-2.1), respectively. ConClusions: The results showed that efficacy 
and safety of biosimilar infliximab is not significantly different from innovator 
infliximab and from other biologics.
PMS12
SyStEMatic rEviEw coMParing thE Efficacy and SafEty of 
collagEnaSE cloStridiuM hiStolyticuM (xiaflEx®) injEction 
with Surgical faSciEctoMy for thE trEatMEnt of duPuytrEn’S 
contracturE
Sugden P.1, Cottrell S.1, Tilden D.1, Ballmer A.2
1THEMA Consulting Pty. Limited, Pyrmont, Australia, 2Actelion Pharmaceuticals Australia, 
Belrose, Australia
objeCtives: To compare the efficacy and safety of collagenase clostridium his-
tolyticum (CCH, Xiaflex®) injection with surgical fasciectomy for the treatment 
of Dupuytren’s contracture (DC). Methods: Systematic review and qualitative 
synthesis of comparative and non-comparative studies reporting efficacy (clini-
cal success, recurrence of contracture) and safety (complication) outcomes for 
patients undergoing fasciectomy for DC. Informal non-statistical comparison with 
outcomes from 3 pivotal placebo controlled trials and a long term follow-up study 
of DC patients treated with CCH. Results: Sixty-eight studies of fasciectomy were 
identified for inclusion in the review: 61 case series (52 retrospective; 9 prospec-
tive); 3 randomised controlled trials (RCTs), none of which permitted either a direct 
comparison with CCH or an indirect comparison via a common comparator; 1 RCT 
follow-up study; 2 prospective uncontrolled studies; 1 postal survey. Studies varied 
in terms of fasciectomy technique employed. Follow-up ranged from only immedi-
ately post-operatively up to 35 years post-operatively. Definitions of surgical success 
and recurrence varied, and were frequently ill-defined or less stringent than the 
robust definitions used in the CCH trials. In studies of fasciectomy where defini-
tions were judged as reasonably comparable to those used in the CCH trials (clinical 
success: 14 studies; recurrence: 40 studies), clinical success and recurrence rates for 
CCH and fasciectomy were comparable (clinical success: 63% vs 69% respectively, 
recurrence: 28% vs 21% at 4 years, respectively). Complication rates were greater 
for fasciectomy than for CCH. These included digital nerve or artery injury (3.3% vs 
0%), complex regional pain syndrome (3.6% vs 0.04%), joint stiffening (8.9% vs 0%), 
wound infection (6.2% vs 0%), and paraesthesia (4.3% vs 0%). Tendon ruptures were 
reported with CCH, but were infrequent (0.07%). ConClusions: CCH and surgical 
fasciectomy can be reasonably considered as comparable in terms of efficacy for 
the treatment of DC and superior in terms of safety.
PMS13
coMParativE EffEctivEnESS of activE vErSuS ShaM acuPuncturE 
vErSuS uSual carE in thE ManagEMEnt of chronic, non-cancEr Pain 
in PriMary carE
Saramago P.1, Weatherly H.1, Manca A.2, Sculpher M.J.1, MacPherson H.1
1University of York, York, UK, 2University of York, Heslington, UK
objeCtives: To examine the effectiveness of acupuncture net of sham effect and 
usual care, measured using EQ-5D, in the management of chronic, non-cancer pain 
in primary care. Systematic reviews of acupuncture for the conditions osteoarthritis 
PMS8
EQ-5d utility wEightS aSSociatEd with rESPonSE to trEatMEnt with 
Matrix aPPliEd autologouS culturEd chondrocytES (Maci) iMPlant 
and MicrofracturE for cartilagE dEfEctS of thE knEE
Saris D.1, Brittberg M.2, Mehin N.3, Dehle F.4, Dowton D.4, Kili S.5, Price A.6
1University Medical Center Utrecht, Utrecht, The Netherlands, 2Region Halland Orthopaedics, 
Kungsbacka, Sweden, 3Sanofi Biosurgery, Paris, France, 4OptumInsight, Sydney, Australia, 5Sanofi 
Biosurgery, Oxford, UK, 6Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal 
Sciences (NDORMS), Oxford, UK
objeCtives: SUMMIT, a 2-year, multicenter, randomised trial, demonstrated signifi-
cant improvements in pain and function with matrix applied autologous cultured 
chondrocytes (MACI) implant versus microfracture in patients with symptomatic 
knee cartilage defects (NCT00719576). We present post-hoc results of the impact of 
treatment response on EQ-5D utility scores, and the overall incremental impact of 
treatment with MACI compared with microfracture over 2 years. Methods: Patients 
(aged 18-55) with Outerbridge Grade III/IV focal cartilage defect ≥ 3.0cm2were ran-
domised to receive MACI implant (n= 72) or microfracture (n= 72). Response to treat-
ment was defined as ≥ 10-point improvement from baseline in both the Knee Injury 
and Osteoarthritis Outcome (KOOS) pain and function scores at year 2. EQ-5D was 
evaluated at baseline, and years 1 and 2. Patients’ EQ-5D responses were scored using 
UK-tariffs. Utility values associated with responders and non-responders were esti-
mated based on results from both treatment arms combined. Incremental quality-
adjusted life year (QALY) gains were derived by multiplying the difference in response 
rates between the treatments with the difference in utility between responders and 
non-responders. Results: The mean utility score for all patients (n= 142) at base-
line was 0.481±0.296. Responders (n= 111) had an improvement in mean utility score 
from baseline of 0.352 (0.833-0.481) compared with 0.033 for non-responders (n= 29; 
0.514-0.481) at year 2. Significantly more patients treated with MACI responded to 
treatment than with microfracture (87.5% vs. 68.1%, respectively; p= 0.016), result-
ing in an incremental QALY gain of 0.11 for MACI compared with microfracture over 
2 years. ConClusions: At baseline, patients with chondral defects experienced a 
substantially reduced HRQoL. Significantly more patients responded to treatment 
with MACI versus microfracture, and this response was associated with substantial 
improvements in HRQoL. In this population, the higher response rate for MACI resulted 
in an incremental QALY gain of 0.11 compared with microfracture over 2 years.
PMS9
Early rESPonSE to cErtolizuMaB PEgol in rhEuMatoid arthritiS 
PrEdictS outcoME at onE yEar
Berenbaum F.1, Pham T.2, Fautrel B.3, Joubert J.M.4, De Chalus T.4, Riou França L.5, 
Claudepierre P.6
1CHU Saint-Antoine, Paris, France, 2CHU Sainte-Marguerite, Marseille, France, 3CHU Pitié-
Salpétrière, Paris, France, 4UCB Pharma, Colombes, France, 5Phisquare Institute, Paris, France, 
6Groupe Hospitalier Henri Mondor, Créteil, France
objeCtives: Treat-to-target strategies for the treatment of rheumatoid arthritis 
(RA), as recommended in current treatment guidelines, require the use of reliable 
early markers of treatment response in order to adapt therapy in a timely way in 
patients with insufficient response. The objective of this study was to evaluate 
and compare the performance of different clinical indicators in predicting clini-
cal response at one year. Methods: This was a post-hocanalysis of data from the 
RAPID1 randomised, placebo-controlled Phase III study. A total of 382 severe RA 
patients treated with certolizumab pegol 200mg and no prior TNF inhibitor were 
assessed by Week 12 (bW12) and at Week 52 (W52). “Insufficient response” was 
defined using the ACR response criteria, compared to baseline, DAS28 score (Δ < 1.2), 
HAQ score (Δ < 0.22) and CDAI (score< 22). The ability of insufficient response to 
these markers bW12 to predict failure to achieve ACR50 at W52, was compared in 
terms of positive predictive value (PPV), specificity and sensitivity. Results: At 
W52, 149 (38.1%) patients met the ACR50 response criterion. For all bW12 outcome 
indicators, the specificity and the PPV was > 80%. The higher PPVs were observed 
for bW12 ACR20 non response (1.00 [95%CI: 0.93-1.00]), bW12 reduction in DAS28 
(0.95 [95%CI: 0.82-0.99]) and bW12 CDAI score (0.93 [95%CI: 0.85-0.97]). For bW12 
ACR20 non response, bW12 reduction in DAS28 and bW12 CDAI score, specificities 
were respectively 1.00 (95%CI: 0.97-1.00), 0.99 (95%CI: 0.94-1.00) and 0.95 (95%CI: 
0.90-0.98). The highest sensitivity was observed for the bW12 ACR50 (0.70 [95%CI: 
0.63-0.76]). ConClusions: All these early response markers have high PPV and 
high specificity but low-to-moderate sensitivity: 80% to 100% of patients identified 
as “insufficient-responders” by W12 would fail to fulfil the ACR50 response at W52. 
Such predictability data for certolizumab pegol should help physicians to make early 
decisions about the potential discontinuation of the treatment.
PMS10
thE 3d o-arM Surgical iMaging SyStEM with navigation EffEctivEly 
and EconoMically addrESSES thE challEngES of SPinal StaBilization 
ProcEdurES
Annoni E.1, Joedicke H.1, Barnett G.S.2
1Medtronic International, Tolochenaz, Switzerland, 2Gillian Barnett & Associates Ltd., 
Dunfanaghy, County Donegal, Ireland
bACkgRound: Inaccurate pedicle screw placement and neurological or vascu-
lar injury during spinal instrumentation procedures is both costly and prevent-
able. objeCtives: To determine the comparative efficacy or effectiveness and 
value for money of the 3D O-arm Surgical Imaging System with Navigation during 
spinal stabilization surgery compared with standard practice. Methods: A search 
of Medical and Health Economic electronic databases (Embase, PubMed, HEED, 
NHS EED, Cochrane) and conference abstracts up to Nov. 2012 was conducted to 
identify studies evaluating the effectiveness, efficacy and economics of 3D surgical 
imaging with navigation. No time or language restrictions were applied. Results: 
Compared with current practice options, the 3D O-arm surgical imaging with navi-
gation was shown to significantly increase the accuracy of instrument placement, 
reduce surgeons’ and patients’ exposure to radiation, and offer the opportunity for 
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PMS16
uPtakE of dEnoSuMaB in thE trEatMEnt of oStEoPoroSiS in thE czEch 
rEPuBlic
Fuksa L., Vytrisalova M.
Charles University, Faculty of Pharmacy, Hradec Kralove, Czech Republic
objeCtives: The objective was to analyze current trends in consumption as well 
as prescription practice pattern of the new anti-RANKL monoclonal antibody 
denosumab in the treatment of osteoporosis since its introduction onto the mar-
ket in the Czech Republic in 2011. Methods: The prescription-based database of 
the General Health Insurance Company (VZP) of the CR that covers approximately 
62% of the Czech population was used as the data source. An insured person with 
a recorded prescription for denosumab in the period of interest was defined as a 
patient. The obtained epidemiological and costing data were also confronted with 
the prediction in the budget impact analysis in the public reimbursement dossier 
accessible in the State Institute for Drug Control files. Results: A total of 3119 (158) 
patients (men) treated with denosumab were identified in the first year, i.e. between 
August 2011 and July 2012. The median age of patients was 73 years. Of the patients 
prescribed denosumab in the first half-year, 84% received the second dose within 
the observed period of one year, of which 85% within the authorized period of 6 
months (+-1 month). This new drug was most often prescribed by physicians trained 
in internal medicine (47%) and rheumatology (30%). The cumulative costs for VZP 
of the drug were CZK 27.3 mil (EUR 1.1. mil) in the first year. ConClusions: The 
uptake of denosumab has been rapid and agrees with the predictions presented by 
the manufacturer before the launch of the drug. This preliminary data also suggest 
that both the prescribing doctors and the patients filling the prescriptions follow 
the dosing schedule.
PMS17
thE uSE of Biologic drugS for thE trEatMEnt of rhEuMatoid 
arthritiS in italy
Heiman F.1, Katz P.1, Pegoraro V.1, Di V.irgilio R2
1CSD Medical Research S.r.l., Milan, Italy, 2Pfizer Pharmaceuticals, Rome, Italy
objeCtives: To describe the clinical profile of patients with rheumatoid arthri-
tis (RA) treated with biologic agents within the former Italian centers “Antares” 
where autoimmune diseases are treated. Methods: This study analyzed data from 
patient diaries (PDS), which involved 70 rheumatologists that are regular prescribers 
of biological treatments for rheumatoid arthritis and were recruited by telephone. 
The patient diaries were completed via web. Results: Study population consisted 
of 206 (45.9%) patients with RA, 160 (35.6%) with psoriatic arthritis, 61 (13.6%) with 
ankylosing spondylitis, 14 (3.1%) with Juvenile idiopathic arthritis and 8 (1.8%) with 
early RA. Female gender prevailed, while the most numerous age group was the 
one that ranged from 50 to 60 years. The disease was mostly diagnosed before 50 
years old and, despite in the group of patients treated with biologic drugs for more 
than 3 months the percentage of subjects with a value of HAQ less than 1 is higher 
when compared with those of patients whose treatment has begun more recently, 
the proportion of patients with a value of HAQ between 2 and 3 is still 40.0%. The 
same, half of the subjects treated for more than 3 months still have a moderate or 
high disease activity (DAS28 ≥ 3.2). ConClusions: The study sample was in line 
with the literature concluding that it is representative of the Italian context. The 
fact that there is a proportion of patients treated with biological therapy for more 
than three months, as well as an important number of patients who have been 
treated with more than one biologic drugs, and that have a perception of quality of 
life rather low and / or a disease activity state rather active, leads to conclude that 
there is still a type of patient for which new therapeutic options should be evaluated.
PMS18
EStiMatEd oStEoPorotic PoPulation and thE rElatEd MEdication 
conSuMPtion in MuniciPality lEvEl – diScrEPanciES oBSErvEd 
through data viSualization aPProach
Säävuori N.1, Tyrväinen V.2, Purmonen T.3
1Oy Medfiles Ltd., Vantaa, Finland, 2Proper Ltd., Joensuu, Finland, 3Oy Medfiles Ltd., Kuopio, 
Finland
objeCtives: Osteoporosis is a common health problem among elderly popula-
tion. Patients with osteoporosis are exposed to low-energy fractures. The preva-
lence of the disease varies significantly throughout the country due to the strong 
correlation with demographic factors. National guidelines recommend secondary 
prevention for all osteoporosis patients suffering from low-energy fractures. The 
aim of treatment is to prevent further fractures. In order to effectively allocate the 
resources needed for osteoporosis treatment, it is essential to know the number 
of patients and treatment practices in local level. Methods: Local registry data 
was used to estimate the total population with low-energy fractures, as well as 
to recognize the differences in treatment of osteoporosis in each hospital district 
(n= 21) and municipality (n= 320). Data on hip fractures from year 2009 was extrapo-
lated to year 2012 using demographic data. The overall prevalence of low-energy 
fractures was estimated trough a distribution of different fracture types available 
from literature. A map-based application was built (Tableau 8) to visualize the dif-
ferences in the prevalence and treatment of osteoporosis across Finland. The model 
enables comparison between municipalities or hospital districts. Results: The 
estimated number of osteoporotic fractures was 1733, in a hospital district with 
250,000 inhabitants (Northern-Savo). The estimated prevalence rates in different 
municipalities within the hospital district varied between 0.52–1.7/100 inhabit-
ants. Simultaneously, basic reimbursement for medical treatment (ATC:M05B) was 
paid for 1.2/100 inhabitants - the range among elderly population (> 65y) was 3.21– 
6.56/100 inhabitants. ConClusions: There are significant local differences in the 
prevalence of osteoporosis as well as in its treatment. The population demographics 
do not explain the observed differences in the consumption of osteoporosis medica-
tion between different municipalities. The developed map-based application gives 
multiple possibilities to analyze these issues through data visualization. With this 
approach the interventions may be targeted to areas needing it the most.
of the knee, musculoskeletal pain and headache have been published however no 
reviews have incorporated the latest trial evidence from the recent large scale high 
quality RCTs to generate EQ-5D scores. Methods: An individual patient level data 
(IPD) based Mixed Treatment Comparison (MTC) was undertaken using a database 
of 28 recent, high quality RCTs containing observations for over 18,000 patients. 
The analysis evaluated the effectiveness of acupuncture in terms of continuous 
outcomes, for each of the three conditions over a three month time horizon, map-
ping generic and disease-specific measures to generate EQ-5D scores and using 
published mapping algorithms unless none were available. Results: Acupuncture, 
net of sham, is more effective in that it generates greater EQ-5D scores compared to 
usual care in the management of chronic, non-cancer pain in primary care. Using 
a random effects IPD MTC, the change in EQ-5D scores from baseline to 3 months 
was mean 0.0419 (95% credibility interval 0.0066 to 0.0765) for acupuncture net 
of sham and 0.0573 (95% credibility interval 0.0139 to 0.1006) for acupuncture vs 
usual care. ConClusions: Based on EQ-5D scores, this analysis suggests that 
acupuncture, is the most effective option. The analyses synthesise effectiveness 
evidence using MTC of IPD whilst controlling for sham effect. This analysis is an 
intermediate step to inform a full cost-effectiveness analysis to support decision-
making in the UK.
PMS14
aPPlication of a data viSualization tool: trEatMEnt PattErnS of 
vEtEran PatiEntS with ankyloSing SPondylitiS
Baser O.1, Wang L.2, Li L.2, Huang A.2, Xie L.3
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, 
Dallas, TX, USA, 3STATinMED Research, Ann Arbor, MI, USA
objeCtives: As outcomes research methodologies advance, they should increas-
ingly allow access by different disciplines as clinicians, epidemiologists, econo-
mists, and statisticians interact frequently. A data visualization tool can present 
complex patterns effectively to a diverse audience. The objective of this study 
was to present treatment patterns among Veterans Health Administration (VHA) 
patients diagnosed with ankylosing spondylitis (AS) using advanced data visuali-
zation techniques. Methods: Using the VHA Medical SAS®dataset, adult patients 
with at least one AS diagnosis (ICD-9-CM: 720.0) were selected. Prescriptions for 
anti-tumor necrosis factor (anti-TNF) and non-TNF agents were identified. For 2 
years after the date of the first prescription (initiation date), drug switches and 
discontinuation were examined. Using a processing language, a data visualization 
tool was developed to demonstrate changes in treatment patterns after the first 
and second treatment switches. Results: A total of 1,021 AS patients initiated 
therapy with TNF, of which 13.52% switched to another TNF, 0.20% switched to a 
non-TNF, 49.56% discontinued therapy and 36.73% continued their initial therapy. 
Among patients who switched to another TNF, 60.87% remained on the switched 
therapy, while 31.16% discontinued therapy, 7.97% switched to another TNF, and 
no patients switched to a non-TNF. 81.82% of patients who made a second switch 
to a TNF medication remained on this TNF, while 9.09% discontinued treatment. 
A total of 84 AS patients initiated therapy with a non-TNF. 4.76% of these patients 
switched to a TNF, 1.19% switched to another non-TNF, 93.61% discontinued therapy 
and no patients continued treatment. Of those patients whose first switch was to a 
TNF, 50% continued therapy while the remaining 50% discontinued. There were no 
second switches. ConClusions: When analyzing several years of data including 
treatment (dis)continuation and switches, treatment patterns can be difficult to 
capture. Data visualization tools help present complicated flows effectively for a 
diverse research audience.
PMS15
iMProvEMEnt in diSEaSE activity ScorES aSSociatEd with Early 
vErSuS latE initiation of Biologic thEraPy in PatiEntS with 
rhEuMatoid arthritiS: rESultS of a EuroPEan chart rEviEw Study
Emery P.1, Solem C.T.2, Macahilig C.P.3, Majer I.M.4, Stephens J.M.2, Cappelleri J.C.5, Tarallo M.6
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objeCtives: Recent research has suggested that patients may have a “window of 
opportunity” to reverse immune dysregulation associated with RA onset through 
aggressive early treatment. This study aimed to evaluate the outcomes associ-
ated with early versus late biologic treatment in RA. Methods: Adults (≥ 18 
years) with confirmed RA diagnosis between January 2008 and December 2010, 
who received biologic therapy for ≥ 3 months and had ≥ 12 months follow-up 
were included in this retrospective, observational medical chart review study in 
Spain, Germany, and United Kingdom. Physicians abstracted outcomes including 
28-joint disease activity scores (DAS28) alongside treatment received. Patients 
were classified as receiving early biologic treatment if started within 1 year of 
RA diagnosis. Outcomes included DAS28 reduction of ≥ 1.2 from scores at biologic 
start and remission (DAS28< 2.6). Time to reaching these outcomes was evaluated 
using Kaplan-Meier survival curves and log rank tests. Results: Of 328 patients 
included, 310 (178 early; 132 late) had DAS28 measurements and were demographi-
cally similar between early vs. late treatment (overall: mean age 47.9 at diagno-
sis, 71.0% female, 96.1% white). Overall, 73.5% of patients had a DAS28 decrease 
≥ 1.2 points and 44.5% achieved remission. More early versus late biologic treated 
patients had a DAS28 decrease ≥ 1.2 (79.2% vs 65.9%, p= 0.009) but there was no 
significant difference in the time to this decrease. More early vs. late biologic 
treated patients achieved remission (51.1% vs. 35.6%, p= 0.009), with a significant 
difference in survival curves when indexing on time since RA diagnosis (p< 0.001) 
and biologic start (p= 0.024). There were no significant differences outcomes across 
countries. ConClusions: This chart review contributes to the growing literature 
surrounding outcomes associated with early biologic treatment. Within this study, 
RA patients who were treated early were more likely to achieve clinically signifi-
cant improvement and to reach remission earlier in their RA disease trajectory 
than those treated later.
